马来酸罗格列酮治疗2型糖尿病的临床观察.DOCVIP

临床医学论文-马来酸罗格列酮治疗2型糖尿病的临床观察 【关键词】? 2型糖尿病 　　【摘要】? 目的? 探讨噻唑烷二酮类胰岛素增敏剂马来酸罗格列酮（文迪雅）治疗2型糖尿病的临床疗效。方法? 将97例口服磺脲类降糖药血糖控制不满意的2型糖尿病患者随机分为两组，对照组加服盐酸二甲双胍250mg tid治疗，治疗组加服文迪雅4mg qd治疗，疗程均为12周，将两组疗效进行比较。结果? 两组治疗后与治疗前比较FBG、2hBG、HbA1C、FINS、IRI、TG均显著降低（P＜0.05），而治疗组与对照组比较经治疗后上述指标均明显降低，HDL-C增高（P＜0.05），差异有显著性，且用文迪雅治疗无严重副作用。结论? 文迪雅对2型糖尿病患者有明显改善胰岛素抵抗、降低血糖及调节脂代谢异常等作用，是治疗2型糖尿病有效和安全的口服降糖药物。 　　【关键词】? 2型糖尿病；马来酸罗格列酮(文迪雅) 　　Clinical observation of effect of Rosiglitazone (Avandia) in treating type 2 diabetes mellitusLI Qing,GONG Xi-li,LIU Yu-jin.Department of Endocrinology, Xiangdong Hospital, Hunan Normal University, Liling 412200,China 　　【Abstract】? Objective? To observe the clinical effect of in treating type 2 diabetes mellitus.Methods? 97 cases of type 2 diabetes mellitus patients with oral monotherapy of sulphonyluea and bad blood glucose control were selected. They were randomly divided into two groups,one of them was assigned to receive advandia for 12 weeks,but another received metformin for 12 weeks. And the clinical effect of the two groups were compared in treating type 2 diabetes mellitus.Results?Both two groups were observed significantly reduction in fasting blood glucose(FBG),2 hour postprandial blood-glucose(2hBG),mean glycosylated hemoglobin A1C values(HbA1C),fasting plasma insulin(FINS), insulin resistance index(IRI) and serum triglyceride(TG). The levels of FBG,2hBG,HbA1C,FINS,IRI,TG were significantly decreased and serum HDL-C was increased in the group received advandia than the group received metformin（P＜0.05）,The diffence was obvious between the two groups. The side effect was not observed.Conclusion? Rosiglitazone(avandia) is effective in decreasing the level of blood glucose,resversing insulin resistance and adjusting the disorder of lipid metabolism. Rosiglitazone(avandia) is an effective and safe drug in treating type 2 diabetes mellitus. 　　【Key words】? type 2 diabetes mellitus；rosiglitazone 　　糖尿病（diabetes mellitus,DM）是一种常见病，它已成为继心血管、肿瘤之后引起人类死亡的第三大杀手，而2型糖尿病占全部糖尿病人的9